ERBB2 and breast carcinoma: Further evidence for T-DM1 in a range of disease stages was provided by data from clinical trials such as KATHERINE, which established its use even in early-stage HER2-positive breast cancer as adjuvant treatment for patients with residual invasive disease after neoadjuvant HER2-targeted therapy.